CRIS Current Research Information System

SOVERINI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.086
AS - Asia 18.069
EU - Europa 13.273
AF - Africa 1.090
Continente sconosciuto - Info sul continente non disponibili 1.090
SA - Sud America 1.073
OC - Oceania 31
Totale 54.712
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.685
VN - Vietnam 5.167
SG - Singapore 4.614
CN - Cina 4.413
GB - Regno Unito 3.800
IT - Italia 1.889
SE - Svezia 1.832
DE - Germania 1.623
HK - Hong Kong 1.170
IN - India 882
FR - Francia 868
BR - Brasile 761
RU - Federazione Russa 657
NL - Olanda 524
IE - Irlanda 471
UA - Ucraina 389
ZA - Sudafrica 335
JP - Giappone 331
TG - Togo 289
KR - Corea 280
EE - Estonia 244
CA - Canada 224
BD - Bangladesh 222
FI - Finlandia 208
CI - Costa d'Avorio 176
CH - Svizzera 172
JO - Giordania 143
AR - Argentina 133
BG - Bulgaria 121
NG - Nigeria 116
PH - Filippine 108
ID - Indonesia 99
GR - Grecia 95
IR - Iran 93
IQ - Iraq 92
BE - Belgio 76
PL - Polonia 71
SC - Seychelles 69
TH - Thailandia 69
TR - Turchia 69
AT - Austria 61
MX - Messico 60
EC - Ecuador 57
TW - Taiwan 51
SA - Arabia Saudita 47
ES - Italia 43
PK - Pakistan 40
UZ - Uzbekistan 29
AU - Australia 27
CZ - Repubblica Ceca 27
MY - Malesia 27
CO - Colombia 26
CL - Cile 24
VE - Venezuela 24
JM - Giamaica 22
LB - Libano 21
AE - Emirati Arabi Uniti 20
MA - Marocco 20
EG - Egitto 19
RO - Romania 18
CR - Costa Rica 17
HN - Honduras 17
PY - Paraguay 17
ET - Etiopia 13
TN - Tunisia 13
LT - Lituania 12
PE - Perù 12
GT - Guatemala 11
IL - Israele 10
KE - Kenya 10
NP - Nepal 10
PS - Palestinian Territory 10
TT - Trinidad e Tobago 10
UY - Uruguay 10
DZ - Algeria 9
NI - Nicaragua 9
RS - Serbia 9
NO - Norvegia 8
SK - Slovacchia (Repubblica Slovacca) 8
SV - El Salvador 8
EU - Europa 7
AZ - Azerbaigian 6
MK - Macedonia 6
OM - Oman 6
PA - Panama 6
PT - Portogallo 6
QA - Qatar 6
BO - Bolivia 5
DK - Danimarca 5
KZ - Kazakistan 5
LY - Libia 5
PR - Porto Rico 5
XK - ???statistics.table.value.countryCode.XK??? 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AL - Albania 4
BA - Bosnia-Erzegovina 4
BY - Bielorussia 4
MD - Moldavia 4
MN - Mongolia 4
SY - Repubblica araba siriana 4
Totale 53.567
Salva come PNG Salva come JPEG
Città #
Southend 3.456
Singapore 3.225
Ashburn 1.970
Fairfield 1.809
Chandler 1.559
Dong Ket 1.250
Hong Kong 1.103
San Jose 969
Houston 959
Ho Chi Minh City 934
Woodbridge 924
Wilmington 859
Seattle 827
Beijing 736
Hanoi 729
Princeton 672
Ann Arbor 648
Cambridge 613
Hefei 519
Santa Clara 515
Dublin 469
Boardman 439
Bologna 341
Lauterbourg 337
Council Bluffs 335
Nanjing 327
Westminster 304
Lomé 289
Los Angeles 287
Tokyo 282
New York 277
Padova 273
Seoul 206
Dallas 195
Abidjan 175
Helsinki 173
Berlin 169
Medford 162
Jacksonville 159
Shenyang 158
Buffalo 146
Jinan 140
Chicago 139
Amman 138
Bern 137
Haiphong 135
Redmond 135
Milan 128
Saint Petersburg 120
Da Nang 118
Frankfurt am Main 117
Sofia 117
São Paulo 117
Redondo Beach 115
Nanchang 113
Turin 109
Hebei 108
San Diego 108
Changsha 106
Munich 95
Guangzhou 93
Rome 88
Shanghai 86
Bremen 85
Abeokuta 81
Tianjin 81
Brussels 75
Zhengzhou 72
Florence 69
Jiaxing 69
Falls Church 64
Phoenix 64
Hangzhou 62
Toronto 60
Orem 58
London 57
Norwalk 56
Nuremberg 56
Bengaluru 53
Biên Hòa 51
Johannesburg 51
Haikou 48
Jakarta 48
Baghdad 47
Mülheim 47
Warsaw 47
Montreal 46
Redwood City 44
Ningbo 43
Des Moines 42
Taizhou 42
Hải Dương 41
Brooklyn 39
Falkenstein 39
The Dalles 39
Can Tho 37
Taiyuan 35
Ha Long 34
Thái Nguyên 34
Yubileyny 34
Totale 34.291
Salva come PNG Salva come JPEG
Nome #
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 668
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 394
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 358
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia 356
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 355
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 320
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 318
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 318
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 308
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 306
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 304
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 295
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 287
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy 281
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 279
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 271
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 271
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 268
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells 263
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 261
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 258
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 256
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 250
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 250
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 250
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 248
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 243
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 242
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 240
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 238
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 236
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 235
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 233
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 232
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 230
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 226
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 224
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 223
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 222
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 222
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 219
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 218
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 217
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 215
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 215
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 214
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 212
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 211
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 210
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 210
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 210
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 207
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 205
c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration 204
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 204
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 204
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 204
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 203
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 203
Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia 202
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 202
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 202
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 202
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy 200
Analisi di polimorfismi in geni coinvolti nel ciclo dei folati come determinanti di suscettibilità a leucemia mieloide cronica. 196
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 196
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 194
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 194
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 193
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 191
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 190
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 189
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 188
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 188
Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model 187
Association between transporters genotype and response to the treatment in a subset of previously untreated chronic myeloid leukemia patients enrolled into the tops trial. 186
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 186
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 186
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 185
Advances in the biology and therapy of chronic myeloid leukemia (CML): Proceedings from the 6(th) Post-ASH International CML and Myeloproliferative Neoplasms Workshop. 183
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 181
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 181
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 181
CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies 180
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 179
Clec12a: A new AML stem cell-associated antigen 179
The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities 178
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 177
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 176
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 176
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 176
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 176
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 176
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 176
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 175
A novel framework for chimeric transcript detection based on accurate gene fusion model 175
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 175
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia 174
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 174
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 173
Totale 22.802
Salva come PNG Salva come JPEG
Categoria #
all - tutte 150.378
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 150.378
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.315 0 141 391 459 624 418 105 422 299 397 1.025 1.034
2022/20236.558 761 1.054 346 821 461 475 281 349 1.055 148 534 273
2023/20241.671 68 287 95 163 114 412 99 106 68 77 83 99
2024/20256.561 243 1.151 619 459 830 314 521 195 91 611 288 1.239
2025/202616.190 1.184 1.731 1.548 1.070 1.781 883 1.501 593 3.430 1.379 677 413
2026/20271.401 468 933 0 0 0 0 0 0 0 0 0 0
Totale 54.712